Observational, retrospective, single-institution cohort (2011–2023) of 106 consecutive adult patients harboring supratentorial grade 3 gliomas, IDH-mutant treated by maximal awake resection and who received a watch-and-wait approach (surgery group) or an adjuvant oncological treatment (oncological group) postoperatively. Here, IDH1 is linked to central nervous system cancer.